drugset / Trial / NCT06549257
Assessing the Safety, Immunogenicity and Ex-vivo Efficacy of Two Candidate Malaria Transmission Blocking Vaccines, Pfs25-IMX313 and Pfs45/48 Administered Alone and in Combination, in Matrix-M Adjuvant
Phase 1/2
Active not recruiting
56 enrolled
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Assessing the safety, immunogenicity and ex-vivo efficacy of two transmission blocking vaccines (Pfs25-IMX313 in Matrix M and Pfs48/45 in Matrix M alone and co-administered) in Burkina Faso, in 18-45 years, 12-17 years and 05-11 year olds.
Timeline
- Start
- 2025-07-07
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pfs25-IMX313 | Vaccine | 10 ug | — |
| Subject | Pfs48/45 | Unknown | 10 ug | — |